• 3. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. (nih.gov)
  • The goal of this initiative is to advance our knowledge of basic stem cell biology in areas of stem cell isolation, quantitation by in vivo assay, in vitro and in vivo growth and expansion, gene insertion and expression, and engraftment. (nih.gov)
  • Here, we present an unplanned exploratory analysis evaluating the hematopoietic reconstitution kinetics, engraftment and clonality in 13 pediatric Wiskott-Aldrich syndrome patients treated with autologous lentiviral-vector transduced hematopoietic stem/progenitor cells derived from mobilized peripheral blood (n = 7), bone marrow (n = 5) or the combination of the two sources (n = 1). (bvsalud.org)
  • In vitro differentiation and transplantation studies in mice confirm that primitive hematopoietic stem/progenitor cells from both sources have comparable engraftment and multilineage differentiation potential. (bvsalud.org)
  • Mesenchymal stromal cells (MSCs) have been employed in vitro to support hematopoietic stem and progenitor cell (HSPC) expansion and in vivo to promote HSPC engraftment. (bvsalud.org)
  • The use of BM-MSCs resulted in superior human engraftment and increased clonal output of GE-HSPCs contributing to the early phase of hematological reconstitution in the peripheral blood of transplanted mice. (bvsalud.org)
  • We characterized the short-term (8 weeks) engraftment in NOD/SCID mice resulting from transplanted CD34 + cells from these two sources. (johnshopkins.edu)
  • We observed robust engraftment of patient-derived cells at 12 weeks post-transplant regardless of their genetic background or donor patient disease severity (Fig 1A). (confex.com)
  • The reduced-toxicity myeloablative conditioning regimen, FBC, is the combination of Bu, Cy, and fludarabine (Flu), which has a strong immunosuppressive effect to ensure the success of engraftment of donor cells. (clinicaltrials.gov)
  • HSCT is an important therapy for the treatment of high-risk malignant hematological diseases, which could eliminate tumor cells through high-dose radiotherapy or chemotherapy, destroy the immune system of patients to prepare the engraftment of donor cells, and promote the reconstitution of hematopoiesis and immune recovery. (clinicaltrials.gov)
  • 11 While it took one hour to maximally mobilise HSCs/HPCs to the blood of mice, it took six to nine hours to maximally mobilise human CD34+ cells (which contain HSCs/HPCs, but are not a pure population of these cells), HPC and CD34+ human cells with functional HSC capacity as assessed by their engraftment of mice with a non-obese diabetic (NOD)/severe combined immunodeficiency (SCID) genotype. (touchoncology.com)
  • 0001). The time to neutrophil and platelet engraftment and graft durability after transplantation were similar across treatment arms. (hematologyadvisor.com)
  • Potency, Proliferation and Engraftment Potential of Stem Cell Therapeutics: The Relationship between Potency and Clinical Outcome for Hematopoietic Stem Cell Products. (preferred-cell-systems.com)
  • Many studies of allogeneic marrow transplantation have shown that a higher dose of marrow cells correlates with a stronger hematopoietic engraftment and lower mortality from infectious complications. (nih.gov)
  • Secondary end points included post-transplantation incidences of neutrophil and platelet engraftment, graft failure, acute and chronic GVHD, relapse, and infections. (nih.gov)
  • Patients with LPD who presented at an early stage and with no history of radiotherapy had faster neutrophil engraftment after APBSCT, while a younger age at transplantation with a higher dose of CD34+ cells may predict faster platelet engraftment. (omjournal.org)
  • Research Objective We aim to demonstrate that regulators of endothelial cell permeability can foster engraftment of endothelial cell progenitors in the liver sinusoids leading to production of Factor VIII. (ca.gov)
  • We combine index sorting of single cells from the embryonic aorta-gonad-mesonephros region with endothelial cell co-culture and transplantation to characterize the phenotypic properties and engraftment potential of single hematopoietic precursors. (jove.com)
  • The overall goal of this method is to identify the phenotypic properties and engraftment potential of clonal Hematopoietic Stem Cell or HSC precursors during murine embryonic development. (jove.com)
  • More specifically, methods for improving engraftment efficiency in stem cell transplants by improving stem cell homing to bone marrow are provided. (justia.com)
  • A Phase 3 clinical trial showed faster neutrophil engraftment and reduced bacterial and fungal infections as compared to standard cord blood transplants. (cryo-cell.com)
  • Results from a phase I-II trial using UM171-expanded CB transplants showed prompt neutrophil engraftment at 18 days, low incidence of infectious complications, rapid resolution of febrile neutropenia, and shorter hospitalization after transplantation when compared to conventional cord blood transplants. (cryo-cell.com)
  • We report the development and characterization of a new genetic stock of IL-2R common γ-chain deficient NOD/LtSz- scid (NOD- scid IL2R γ null ) mice and document their ability to support human mobilized blood HSC engraftment and multilineage differentiation. (aai.org)
  • Engraftment of NOD- scid IL2R γ null mice with human HSC generate 6-fold higher percentages of human CD45 + cells in host bone marrow than with similarly treated NOD- scid mice. (aai.org)
  • Thus, NOD- scid IL2R γ null mice engrafted with human mobilized blood stem cells provide a new in vivo long-lived model of robust multilineage human HSC engraftment. (aai.org)
  • The stem cell source may be bone marrow, peripheral blood, or umbilical cord blood. (medscape.com)
  • The term encompasses multipotent cells derived from other non-marrow tissues, such as placenta, umbilical cord blood, adipose tissue, adult muscle, corneal stroma, or the dental pulp of deciduous (baby) teeth. (wikipedia.org)
  • The youngest and most primitive MSCs may be obtained from umbilical cord tissue, namely Wharton's jelly and the umbilical cord blood. (wikipedia.org)
  • To compare the efficacy and safety of umbilical cord blood mononuclear cells (CBMNC) and azathioprine (AZA) in the treatment of patients with steroid-dependent or -resistant ulcerative colitis. (oncotarget.com)
  • Umbilical cord blood is a rich source of these committed progenitor cells and, presumably, multipotent HPCs (Knudtzon, 1974). (nationalacademies.org)
  • HSCs/HPCs are also found in high numbers in umbilical cord blood (CB) at birth, and circulate in the peripheral blood of adults - although in very low numbers. (touchoncology.com)
  • Mesenchymal stem cells are heterogenous adult multipotent stromal cells that can be isolated from various sources including: bone marrow, peripheral blood, umbilical cord blood, dental pulp, and adipose tissue. (intechopen.com)
  • Development of a novel assay to evaluate the functional potential of umbilical cord blood progenitors. (preferred-cell-systems.com)
  • Detecting primitive hematopoietic stem cells in total nucleated and mononuclear cell fractions from umbilical cord blood segments and units. (preferred-cell-systems.com)
  • Improving quality and potency testing for umbilical cord blood: A New Perspective. (preferred-cell-systems.com)
  • Optimal donor for African Americans with hematologic malignancy: HLA-haploidentical relative or umbilical cord blood transplant. (stembook.org)
  • Gamida Cell investigators showed the expansion of the umbilical cord blood (UCB) stem cells and inhibition of differentiation of the stem cells using nicotinamide in cell culture.2 Median CD34+ cell expansion was 130-fold. (cryo-cell.com)
  • 3 The product is intended for use in adult and pediatric patients 12 years and older with hematologic malignancies who are undergoing umbilical cord blood transplantation following myeloablative conditioning. (cryo-cell.com)
  • Omidubicel vs standard myeloablative umbilical cord blood transplantation: Results of a phase 3 randomized study. (cryo-cell.com)
  • Georg Hansmann, Philippe Chouvarine, Franziska Diekmann, Martin Giera, Markus Ralser, Michael Mülleder, Constantin von Kaisenberg, Harald Bertram, Ekaterina Legchenko & Ralf Hass "Human umbilical cord mesenchymal stem cell-derived treatment of severe pulmonary arterial hypertension" . (anova-irm.com)
  • Preapheresis quantification of circulating CD34+ cells (CD34) may be used to predict peripheral blood progenitor cell (PBPC) yield in subsequent leukapheresis products. (medscape.com)
  • CD34 were analyzed by flow cytometry on blood samples taken immediately prior to leukapheresis and on the resulting harvest products. (medscape.com)
  • Our results confirm that quantification of CD34 in preapheresis blood samples on the day of harvest is a reliable guide for predicting progenitor cell number in subsequent harvest products. (medscape.com)
  • So far, CD34 measurement in peripheral blood before leukapheresis procedures appears to be the most reliable and the most convenient guideline for PBPC harvesting. (medscape.com)
  • These bone marrow stem cells do not contribute to the formation of blood cells, and so do not express the hematopoietic stem cell marker CD34. (wikipedia.org)
  • CD34-/CD133+/VEGFR-2+ endothelial progenitor cell subpopulation with potent vasoregenerative capacities. (nih.gov)
  • We found that 0.5 million CD34 + CB cells were able to generate sustained, high-level, multilineage human hematopoiesis, whereas a sixfold higher number of CD34 + PBSC (3 million) from cancer patients undergoing chemotherapy generated comparable short-term, but much lower sustained multilineage human hematopoiesis after transplantation. (johnshopkins.edu)
  • In comparison to CD34 + cells from PBSC from cancer patients, long-term engrafting cells were approximately eightfold enriched in CB CD34 + cells, and each CB long-term engrafting cell had an ∼15-fold higher multilineage proliferative capacity. (johnshopkins.edu)
  • Peripheral blood stem cells (PBSC) collected after mobilization with granulocyte colony stimulating factor (G-CSF) contain a large number of CD34-positive progenitors and total cells than bone marrow. (nih.gov)
  • In contrast, a patient with systemic sclerosis who was transplantedwith a CD34-selected, T-cell-depleted autograft (0.04 ×10 6 CD3 cells/kg body weight) after conditioning with 200 mg/kg of cyclophosphamide(Cytoxan, Neosar) showed significant disease improvement, although clearlylonger-term follow-up will be required to confirm this effect. (cancernetwork.com)
  • Flow cytometry analysis of CD34 expression on human CD14-negative stem cells from peripheral blood mononuclear cells. (bdbiosciences.com)
  • Fluorescent dot plot depicting CD34 expression was derived from gated events with the forward and side light-scatter characteristics of viable, CD14-negative cells. (bdbiosciences.com)
  • CD34 is a single-chain 105-120 kDa heavily O-glycosylated transmembrane glycoprotein expressed on hematopoietic progenitor cells, vascular endothelium and some tissue fibroblasts. (bdbiosciences.com)
  • 2003). After the early success of transplantation of cord blood from related donors, cord blood banks were established to provide rapidly accessible, human leukocyte antigen (HLA)-typed units predominantly for transplantation of HPCs from unrelated donors. (nationalacademies.org)
  • Blood and Marrow Transplant Research [CIBMTR] in 2004), the European Research Project on Cord Blood Transplantation (Eurocord) in 1993, and the Japanese Cord Blood Banking Network in 1996-expedited the clinical evaluation of the efficacy and safety of transplantation of cord blood from unrelated donors. (nationalacademies.org)
  • With more than 6,000 transplants of cord blood from related and unrelated donors performed thus far, cord blood has emerged as an acceptable, alternative source of HPCs that has some advantages over adult sources of HPCs and the availability of which represents an important development in the field. (nationalacademies.org)
  • Potential donors for allogeneic bone marrow transplantation and patients who underwent elective total hip replacement served as normal controls. (tam-receptor.com)
  • Collection of Peripheral Blood Progenitor Cells in One Day is Associated with Decreased Donor Toxicity compared to Two Days in Unrelated Donors. (stembook.org)
  • To compare survival rates of patients with hematologic cancers that received transplantation of granulocyte colony stimulating factor (G-CSF) mobilized peripheral blood stem cells (PBSC) versus marrow from HLA-compatible unrelated donors. (nih.gov)
  • Peripheral-blood stem-cell donors were prescribed filgrastim or lenograstim at a dose of 10 μg per kilogram per day for 5 days and underwent apheresis. (nih.gov)
  • There was no detected significant survival differences between peripheral-blood stem-cell and bone marrow transplantation from unrelated donors. (nih.gov)
  • Herein, we conducted a non-randomized peripheral blood stem cell (PBSC) mobilization study aimed to compare the potential differences in the expressions of several CAMs and chemokines on CD34+ cells obtained from bone marrow aspirate before and after HPC mobilization from patients with hematologic malignancies and healthy donors. (koreamed.org)
  • Fig. 3 The mean expression of CD106, CD-44, and CD49d on the CD34+ cells assessed in BMA before mobilization and its association with the yield of CD34+ cells collected via LVL in both donors and patients. (koreamed.org)
  • Indication The target indication is for the transplantation of patients with severe X-linked Chronic Granulomatous Disease (XCGD) lacking matched donors. (ca.gov)
  • This study is investigating a new method for collecting blood stem cells from donors to see if it reduces transplant complications, such as rejection, in patients who have blood diseases. (nih.gov)
  • Bone marrow from DsRed-transgenic donors was transplanted into recipients to lineage-trace circulating cells after myocardial infarction (MI). (stanford.edu)
  • Mesenchymal stem cells (MSCs) also known as mesenchymal stromal cells or medicinal signaling cells are multipotent stromal cells that can differentiate into a variety of cell types, including osteoblasts (bone cells), chondrocytes (cartilage cells), myocytes (muscle cells) and adipocytes (fat cells which give rise to marrow adipose tissue). (wikipedia.org)
  • While the terms mesenchymal stem cell (MSC) and marrow stromal cell have been used interchangeably for many years, neither term is sufficiently descriptive: Mesenchyme is embryonic connective tissue that is derived from the mesoderm and that differentiates into hematopoietic and connective tissue, whereas MSCs do not differentiate into hematopoietic cells. (wikipedia.org)
  • Mesenchymal stem cells (MSCs), a term first coined by Arnold I. Caplan in 1991, are characterized morphologically by a small cell body with a few cell processes that are long and thin. (wikipedia.org)
  • These distinctive morphological features of mesenchymal stem cells can be visualized label-free using live cell imaging. (wikipedia.org)
  • As many as 1 in 100 cells collected during amniocentesis are pluripotent mesenchymal stem cells. (wikipedia.org)
  • Cord blood is rich in hematopoietic stem cells, endothelial progenitor cells, mesenchymal stem cells, and other stem/progenitor cells, as well as natural killer cells, Treg cells, and other immune cells, which have strong self-renewal and proliferation ability and low immunogenicity. (clinicaltrials.gov)
  • Although more success has been achieved in preclinical trials on the use of mesenchymal stem cells in animal models than in human clinical trials, particularly in septic shock and Chagas disease, more progress has been made in both disorders after the recent use of specific sources and certain doses of mesenchymal stem cells. (intechopen.com)
  • The clinical application of mesenchymal stem cells in the treatment of several diseases still faces real challenges that need to be resolved. (intechopen.com)
  • The following book chapter will be an updated review on the role of mesenchymal stem cells in various infections and their complications. (intechopen.com)
  • A Phase I Study to Evaluate Two Doses of Wharton's Jelly-Derived Mesenchymal Stromal Cells for the Treatment of De Novo High-Risk or Steroid-Refractory Acute Graft Versus Host Disease. (stembook.org)
  • Within the bone marrow (BM), AML cells interact and communicate with stromal and immune cells and reprogram mesenchymal stromal cells to selectively support leukemic cells, while simultaneously suppressing normal hematopoiesis. (haematologica.org)
  • For example, Bangkok Stem Cell is a Thailand-based cord blood bank that will extract a client's mesenchymal stem cells (MSCs) from adipose tissue and store them for potential future use. (bioinformant.com)
  • To study how Allogro® can induce osteoblast differentiation in mesenchymal stem cells, the expression levels of bone related genes and mesenchymal stem cells marker were analyzed, using real time Reverse Transcription-Polymerase Chain Reaction. (ispub.com)
  • The first is to engraft mesenchymal stem cells (MSCs) onto a graft or a biosynthetic matrix to provide a viable osteoinductive scaffold material for segmental defect repair. (ispub.com)
  • To investigate the osteogenic differentiation of PB-hMSCs, the quantitative expression of the mRNA of specific genes, like transcriptional factors (RUNX2), bone related genes (SPP1, COL1A1, COL3A1, BGLAP, ALPL, and FOSL1) and mesenchymal stem cells marker (CD105) were examined by means of real time Reverse Transcription-Polymerase Chain Reaction (real time RT-PCR). (ispub.com)
  • The reported studies focus on hematopoietic, endothelial and mesenchymal stem cells as they possess a very high capacity for differentiation. (globalstemcells.com)
  • Injectable mesenchymal stem cell therapy for large cartilage defects-a porcine model. (anova-irm.com)
  • Effect of intra-articular injection of autologous adipose-derived mesenchymal stem and regenerative cells on clinical signs of chronic osteoarthritis of the elbow joint in dogs. (anova-irm.com)
  • Increased knee cartilage volume in degenerative joint disease using percutaneously implanted, autologous mesenchymal stem cells. (anova-irm.com)
  • Intra-articular injection of autologous mesenchymal stem cells in six patients with knee osteoarthritis. (anova-irm.com)
  • Adult human mesenchymal stem cells delivered via intra-articular injection to the knee following partial medial meniscectomy. (anova-irm.com)
  • Mesenchymal stem cell therapy in the treatment of osteoarthritis: reparative pathways, safety and efficacy-a review. (anova-irm.com)
  • Mesenchymal stem cells in regenerative medicine applied to rheumatic diseases: role of secretome and exosomes. (anova-irm.com)
  • How do mesenchymal stem cells influence or are influenced by microenvironment through extracellular vesicles communication? (anova-irm.com)
  • Clonal analysis of synovial fluid stem cells to characterize and identify stable mesenchymal stromal cell/mesenchymal progenitor cell phenotypes in a porcine model: a cell source with enhanced commitment to the chondrogenic lineage, Cytotherapy 16 (2014) 776-788. (anova-irm.com)
  • K.B.L. Lee, J.H.P. Hui, I.C. Song, L. Ardany, E.H. Lee, Injectable mesenchymal stem cell therapy for large cartilage defects-a porcine model, Stem Cells 25 (2007) 2964-2971. (anova-irm.com)
  • W.-L. Fu, C.-Y. Zhou, J.-K. Yu, A new source of mesenchymal stem cells for articular cartilage repair: mSCs derived from mobilized peripheral blood share similar biological characteristics in vitro and chondrogenesis in vivo as MSCs from bone marrow in a rabbit model , Am. J. Sports Med. (anova-irm.com)
  • These highlights do not include all the information needed to use HPC, Cord Blood safely and effectively. (nih.gov)
  • See full prescribing information for HPC, Cord Blood. (nih.gov)
  • Hematopoietic Progenitor Cell (HPC), Cord Blood, is an allogeneic cord blood hematopoietic progenitor cell therapy indicated for use in unrelated donor hematopoietic progenitor cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment. (nih.gov)
  • Unit selection and administration of HPC, Cord Blood should be done under the direction of a physician experienced in hematopoietic progenitor cell transplantation. (nih.gov)
  • Do not administer HPC, Cord Blood through the same tubing with other products except for normal saline. (nih.gov)
  • To report SUSPECTED ADVERSE REACTIONS, contact the MD Anderson Cord Blood Bank, The University of Texas MD Anderson Cancer Center, at 1-713-563-8000 and FDA at 1-800-FDA-1088 or https://www.fda.gov/Safety/MedWatch. (nih.gov)
  • Monitor patients and discontinue HPC, Cord Blood infusion for severe reactions. (nih.gov)
  • GVHD is expected after administration of HPC, Cord Blood, and may be fatal. (nih.gov)
  • However, MSCs are found in much higher concentration in the Wharton's jelly compared to cord blood, which is a rich source of hematopoietic stem cells. (wikipedia.org)
  • We therefore characterized leukocyte reconstitution in NSG mice, which were sublethally irradiated and transplanted with human cord blood-derived CD34+ cells at newborn age, longitudinally in peripheral blood and, for more detailed analyses, cross-sectionally in peripheral blood, spleen and bone marrow at different time points. (nih.gov)
  • Cord blood (CB) and autologous mobilized peripheral blood stem/progenitor cells (PBSC) are now used widely for clinical transplantation. (johnshopkins.edu)
  • Leung, W, Ramírez, M & Civin, CI 1999, ' Quantity and quality of engrafting cells in cord blood and autologous mobilized peripheral blood ', Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation , vol. 5, no. 2, pp. 69-76. (johnshopkins.edu)
  • Civin, Curt I. / Quantity and quality of engrafting cells in cord blood and autologous mobilized peripheral blood . (johnshopkins.edu)
  • In the last decade, the number of transplantations of HPCs derived from cord blood has increased, particularly for children. (nationalacademies.org)
  • Since then cord blood banking programs throughout the world have expanded rapidly (Broxmeyer, 1998), with the estimated number of units stored to date exceeding 155,000 (BMDW, 2004). (nationalacademies.org)
  • Post-transplant, BM analysis revealed robust expansion of phenotypically defined MF HSCs relative to cord blood CD34+ control recipients, suggesting a permissive niche for MF HSCs to undergo self-renewal. (confex.com)
  • in France in 1988, cord blood has been widely used as a graft source of hematopoietic stem cells for the treatment of hematological diseases. (clinicaltrials.gov)
  • Some cytokines such as stem cell factor, IL-6, and IL-11 are much higher in cord blood than in peripheral blood. (clinicaltrials.gov)
  • Compared with peripheral blood stem cell transplantation (PBST), UCBT has a higher transplantation rate, as cord blood stem cells are more primitive and purer than bone marrow stem cells. (clinicaltrials.gov)
  • The cord blood industry came into existence in the early 1990's with the formation of several cord blood banks in the U.S. and worldwide. (bioinformant.com)
  • It has been 40 years since it was first proposed that stem and progenitor cells were present in human cord blood. (bioinformant.com)
  • Cord blood banks are rapidly introducing new types of stem cell storage. (bioinformant.com)
  • Although cord blood storage emerged as a commercial service in the early 1990s, cord tissue storage didn't emerge as a commercial service until 2008, when a Taiwanese company, HealthBanks Biotech Company Ltd., began offering the service making it the first company worldwide to do so. (bioinformant.com)
  • Within the U.S., Cord Blood Registry (CBR) was the first private company to begin offering cord tissue storage in July of 2010. (bioinformant.com)
  • Today, nearly all U.S. and most global cord blood banks offer cord tissue storage. (bioinformant.com)
  • In September 2017, Americord Registry became the second U.S. cord blood bank to provide offering placental tissue banking. (bioinformant.com)
  • Internationally, a few dozen cord blood banks offer placental blood and tissue storage services. (bioinformant.com)
  • Some cord blood banks have diversified into the storage of other types of stem cell derivatives, such as dental pulp stem cells. (bioinformant.com)
  • For example, DentCell is a dental pulp stem cell bank controlled by Cryoholdco, the largest cord blood banking operator in the Latin America. (bioinformant.com)
  • Other cord blood banks have expanded into adipose-derived stem cell storage. (bioinformant.com)
  • Cord blood banks are increasing pairing cord blood banking with genetic testing and genomic sequencing services. (bioinformant.com)
  • Natera, a leader in genetic testing, launched its EverCord™ Cord Blood & Tissue Banking Service in March 2017. (bioinformant.com)
  • In September 2019, Natera's Evercord™ business was acquired by Cord Blood Registry, which was previously owned by GI Partners and is now owned by CooperSurgical. (bioinformant.com)
  • LifeCell International, India's largest cord blood bank, offers BabyShield , its preventive prenatal genetic screening and diagnostic testing services. (bioinformant.com)
  • Cordlife, Asia's largest cord blood specialist, partnered with EONE-DIAGNOMICS Genome Center (EDGC), a Korean genetic analysis company, in order to pair cord blood services with genetic testing within East Asian markets. (bioinformant.com)
  • The cord blood industry is also pairing cord blood and tissue banking with fertility and assisted reproduction services. (bioinformant.com)
  • A good example of this trend was GI Partner's acquisition of the largest cord blood bank in the U.S., Cord Blood Registry, for $530 million in June 2018. (bioinformant.com)
  • In January 2020, Generate Life Sciences was formed as an "umbrella" brand to unite CBR, California Cryobank and other legacy brands that were being consolidated, such as Cord Blood America, FamilyCord, EverCord™, and related reproductive and genetic service brands. (bioinformant.com)
  • The bone marrow transplant program led by Dr. Kang is focused on developing improved methods of transplant to treat primary immune deficiencies and includes hematopoietic stem cell transplant using bone marrow, mobilized peripheral blood stem cells, or cord blood from either an HLA-matched sibling or an unrelated donor. (nih.gov)
  • Gamida Cell received FDA approval for its allogeneic cell therapy, Omisirge: a new expanded cord blood cell source for stem cell transplantation. (cryo-cell.com)
  • Historically, usage of cord blood for transplants have been limited by the comparatively lower number of cells as compared to other sources (e.g. bone marrow, peripheral blood apheresis). (cryo-cell.com)
  • 1 Efforts to expand the number of therapeutic cells in cord blood has been researched for decades and now those efforts are set to bear fruit. (cryo-cell.com)
  • 3 Incidence of moderate to serious bacterial or fungal infections through 100 days following transplantation occurred in 39% of patients in the Omisirge arm versus 60% of patients in the standard cord blood arm. (cryo-cell.com)
  • This is a significant milestone for Gamida Cell and for the field of cord blood cell therapy. (cryo-cell.com)
  • Cord blood expansion can greatly impact the therapeutic availability and usage of cord blood and may help the many patients in need of a stem cell transplant. (cryo-cell.com)
  • In other exciting cord blood expansion news, ExCellthera has recently published results of its Phase I/II study investigating its UM-171 product. (cryo-cell.com)
  • 4 Moreover, they achieved this expansion using lower cell dose cord blood units than previous studies. (cryo-cell.com)
  • 2. E. Shpall, K. Rezvani, Cord blood expansion has arrived, Comments on on Horwitz et al, page 1429: Results of a phase 3 randomized study. (cryo-cell.com)
  • Are you scheduled for a stem cell transplant with cord blood? (nih.gov)
  • This study will assess the safety and effectiveness of certain cord blood transplants. (nih.gov)
  • The study will help researchers learn the best methods for collecting, storing, and using cord blood in transplants. (nih.gov)
  • The standard test to confirm multipotency is differentiation of the cells into osteoblasts, adipocytes and chondrocytes as well as myocytes. (wikipedia.org)
  • HMGN1 overexpression also cooperates with the AML-ETO9a fusion oncoprotein to impair myeloid differentiation and enhance leukemia stem cell (LSC) activity. (nature.com)
  • Hematopoiesis is a highly regulated process requiring both self-renewal and differentiation of hematopoietic stem cells (HSCs) to maintain diverse mature blood components. (nature.com)
  • One hallmark of leukemia is a block in normal differentiation from hematopoietic stem/progenitor cells (HSPCs) to their mature progeny. (nature.com)
  • Transplantation of mouse and human HSPCs transduced with an IL-1RA-encoding LV ensured stable IL-1RA production while maintaining the clonogenic and differentiation capacities of HSPCs in vivo. (bvsalud.org)
  • To induce differentiation toward hematopoietic stem cells (HSCs) in vitro, ESCs were cultured in methylcellulose with stem cell factor, interleukin (IL)-3, and IL-6. (rupress.org)
  • B lood cell differentiation begins with multipotent hematopoietic progenitor cells (HPCs), which are located in the marrow spaces of the bone. (nationalacademies.org)
  • These primitive cells undergo division and differentiation to form the various peripheral blood cells. (nationalacademies.org)
  • Abnormal proliferation, clonal expansion, aberrant differentiation, and diminished apoptosis (programmed cell death) lead to replacement of normal blood elements with malignant cells. (msdmanuals.com)
  • The transplant procedure requires the harvesting of hematopoietic stem cells from a donor. (medscape.com)
  • In autologous transplantation, the donor and recipient is the same individual. (medscape.com)
  • When the donor is someone other than the recipient, the procedure is described as allogeneic transplantation. (medscape.com)
  • From 2 wk to 6 mo after injection, the peripheral blood demonstrated increasing ESC-derived mononuclear cells that included donor-derived T and B lymphocytes, monocytes, and granulocytes without clinical or histologic evidence of graft-versus-host disease (GVHD). (rupress.org)
  • Mixed lymphocyte culture assays demonstrated T cell tolerance to both recipient and donor but intact third party proliferative responses and interferon γ production. (rupress.org)
  • ESCs might be used as a renewable alternate marrow donor source that reconstitutes hematopoiesis with intact immune responsiveness without GVHD despite crossing MHC barriers. (rupress.org)
  • a broad range of disorders for which transplantion of HPCs from an adult donor is also successful, including hematological malignancies, solid tumors, constitutional and acquired bone marrow failure syndromes, hemoglobinopathies, congenital immune deficiencies, and inherited disorders of metabolism (Gluckman et al. (nationalacademies.org)
  • We assessed the clonal architecture of engrafted human cells compared to the primary disease in the donor patients through exome sequencing of CD34+ cells prior to transplantation and hCD45+ cells from MF xenografts. (confex.com)
  • Three days after donation of peripheral blood stem cells to a recipient with acute myeloblastic leukemia, dengue virus was detected in the donor, who had recently traveled to Sri Lanka. (cdc.gov)
  • Here, we report transmission of DENV to a peripheral blood stem cell recipient by a donor who had recently traveled to an area to which the virus is endemic. (cdc.gov)
  • The 24-year-old woman, who was registered as a volunteer donor in the German Bone Marrow Donor Registry, was selected. (cdc.gov)
  • To participate in this study, patients must be between the ages of 18 and 65 and have a sibling who is a well-matched stem-cell donor. (nih.gov)
  • Approximately one month later, the patient will be given two immune-suppressing drugs, Campath 1-H and Sirolimus, as well as a single low dose of total body irradiation and then the cells from the donor will be infused. (nih.gov)
  • Clinical trials include studies of gene therapy using either ex vivo lentivector transduction or gene editing of autologous CD34+ hematopoietic stem cells, as well as studies of allogeneic transplantation using matched-sibling donor or matched-unrelated donor (MUD) hematopoietic stem cell grafts with sub-ablative marrow conditioning plus alloimmune tolerance induction regimens. (nih.gov)
  • This study aims to monitor the long-term health of patients who have received a donor stem cell transplant from the NIH Clinical Center. (nih.gov)
  • Additionally, all patients without a sibling donor in complete remission after the first consolidation course were randomized to either autologous peripheral blood stem cell transplantation or a second consolidation course consisting of high-dose cytarabine. (haematologica.org)
  • Conclusions Patients with a donor and candidates for allogeneic stem cell transplantation in first complete remission may have a better disease-free survival than those without a donor in case of myelodysplastic syndromes with intermediate/high-risk cytogenetics. (haematologica.org)
  • 6 - 8 However, the outcome of autologous peripheral blood SCT for patients lacking a suitable donor, appeared, in some studies, comparable to that of allogeneic SCT. (haematologica.org)
  • This Clinical Policy Bulletin addresses hematopoietic cell transplantation for non-hodgkin's lymphoma. (aetna.com)
  • Aetna considers autologous hematopoietic cell transplantation for the treatment of persons with relapsed or primary refractory (see "Note" below) non-Hodgkin's lymphoma (NHL) medically necessary if the person meets the transplanting institution's protocol eligibility criteria. (aetna.com)
  • Aetna considers allogeneic hematopoietic cell transplantation medically necessary for the treatment of persons with relapsed NHL (including persons who have relapsed after autologous hematopoietic cell transplantation) or primary refractory (see "Note" below) NHL (low-grade, intermediate-grade, and high-grade) if the person meets the transplanting institution's protocol eligibility criteria. (aetna.com)
  • Aetna considers non-myeloablative allogeneic hematopoietic cell transplantation medically necessary ("mini-transplant", reduced intensity conditioning transplant) for the treatment of persons with relapsed NHL (including persons who have relapsed after ABMT) or primary refractory (see note below) NHL (low-grade, intermediate-grade, and high-grade) when they are eligible for conventional allografting or a reduced intensity regimen is preferred by the transplant center. (aetna.com)
  • Aetna considers tandem autologous hematopoietic cell transplantion (auto-auto) or tandem autologous hematopoietic cell transplantation followed by allogenic hematopoietic cell transplantation (auto-allo) experimental and investigational for NHL due to a lack of adequate evidence in the peer-reviewed published medical literature of their safety and effectiveness. (aetna.com)
  • Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis. (stembook.org)
  • Outcomes of Allogeneic Hematopoietic Cell Transplantation in T-cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. (stembook.org)
  • Chronic Graft-Versus-Host Disease, Non-Relapse Mortality and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A CIBMTR Analysis. (stembook.org)
  • Content of CD34+ cells in leukapheresis products depends on several factors, including timing of mobilization, the type of chemotherapy used for mobilization, the cytokine(s) added during the postchemotherapy phase to enhance the mobilization and their dosage, the duration of blood processed during the apheresis, and the BM rescue of the patient. (medscape.com)
  • Women with at least partial responses (PRs) to induction therapy received melphalan (140 to 180 mg/m2), followed 24 hours later by chemotherapy and granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral-blood progenitor cells (PBPCs) and subsequent G-CSF until WBC recovery. (nih.gov)
  • 6. Combined chemotherapy and granulocyte colony-stimulating factor (G-CSF) mobilise large numbers of peripheral blood progenitor cells in pretreated patients. (nih.gov)
  • 9. Transplantation potential of peripheral whole blood primed by VACOP-B chemotherapy plus filgrastim (r-metHuG-CSF) in patients with aggressive non-Hodgkin's lumphoma. (nih.gov)
  • 10. Application of whole blood and peripheral blood progenitor cells (PBPC) and new strategies for rescue after intensive cyclic chemotherapy in high-risk breast cancer. (nih.gov)
  • 11. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. (nih.gov)
  • 13. Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma. (nih.gov)
  • Because of the patient's risk status, the physicians intended to perform allogeneic stem cell transplantation after induction and consolidation chemotherapy, which was scheduled to end in January 2013, and a conditioning chemotherapy regimen, which was planned to be given in March. (cdc.gov)
  • Patients who have undergone autologous stem cell transplantation are subsequently more susceptible to chemotherapy-induced bone marrow toxicity. (tam-receptor.com)
  • Chemotherapy, hypomethylating agents (HMA), radiotherapy, targeted therapy, immunotherapy, and hematopoietic stem cell transplantation (HSCT) are common treatments for high-risk malignant hematological diseases. (clinicaltrials.gov)
  • The current research hotspots are HMA combined with chemotherapy, targeted drugs such as BCL-2 inhibitors, immunotherapy, and cell therapy. (clinicaltrials.gov)
  • Clinical Outcomes in Patients With FLT3-ITD-Mutated Relapsed/Refractory Acute Myeloid Leukemia Undergoing Hematopoietic Stem Cell Transplant After Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial. (stembook.org)
  • Further RT-PCR analyses on periph- However, remissions are short and consolidation with eral blood have remained negative, most recently performed chemotherapy is required. (diseasepdf.com)
  • Research Objective Development of a screen using inner ear sensory hair cell-like cells made by direct lineage reprogramming, for discovering drugs to ameliorate hearing loss during cancer chemotherapy. (ca.gov)
  • 1] Furthermore,early reports from Europe imply that unmanipulated peripheral blood orbone marrow autografts are inadequate, as all of the patients who receivedsuch grafts developed disease recurrence after high-dose chemotherapy. (cancernetwork.com)
  • Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. (haematologica.org)
  • Background Allogeneic stem cell transplantation is usually considered the only curative treatment option for patients with advanced or transformed myelodysplastic syndromes in complete remission, but post-remission chemotherapy and autologous stem cell transplantation are potential alternatives, especially in patients over 45 years old. (haematologica.org)
  • Autologous peripheral blood stem cell transplantation does not provide longer survival than intensive chemotherapy. (haematologica.org)
  • 6 , 9 , 10 Moreover, a retrospective study comparing intensive chemotherapy alone against chemotherapy followed by transplantation did not show a clear benefit for chemotherapy followed by SCT. (haematologica.org)
  • In this study, we retrospectively analyzed the results obtained from 113 PBPC leukapheresis procedures performed on 2 groups of patients (49 adults and 21 children) with malignant blood diseases. (medscape.com)
  • HMGN1 amplification is associated with increased accessibility, expression, and histone H3K27 acetylation of loci important for hematopoietic stem cells (HSCs) and leukemia, such as HoxA cluster genes. (nature.com)
  • Importantly, the percentage of more primitive hematopoietic stem cells (HSCs) in bone marrow was maintained over time. (nih.gov)
  • Overall, leukocyte reconstitution was maintained up to 32 weeks post-transplantation in our hu NSG model, possibly explained by the maintenance of HSCs in the bone marrow. (nih.gov)
  • ESC-derived, cytokine-induced HSCs (c-kit + /CD45 + ) were isolated by flow cytometry and injected either intra bone marrow or intravenously into lethally irradiated MHC-mismatched recipient mice. (rupress.org)
  • 1 Haematopoiesis is initiated through rare populations of haematopoietic stem (HSC) and progenitor (HPC) cells that give rise to all blood-forming elements: HSCs/HPCs are found in the bone marrow of adults, where they are produced and nurtured. (touchoncology.com)
  • Numbers of HSCs/HPCs in adult blood can be enhanced by mobilising them out of the bone marrow into the circulation by agents such as granulocyte colony-stimulating factor (G-CSF). (touchoncology.com)
  • Because normal HSCs/HPCs can be used in a transplant setting to cure non-malignant and malignant blood-cell - as well as other non-blood-cell - disorders, knowledge of how HSC/HPC movement is regulated has clinical impact. (touchoncology.com)
  • 1-4 SDF-1/CXCL12 has a number of important functional effects on HSCs/HPCs, 1,5-7 including induction of chemotaxis (directed cell movement) in vitro and migration in vivo and enhancement of survival. (touchoncology.com)
  • The SDF-1/CXCL12 and its receptor, CXCR4, have been implicated in the retention of HSCs/HPCs within the bone marrow microenvironment. (touchoncology.com)
  • It focuses first on the use of AMD3100, a low-molecular- weight antagonist of SDF-1/CXCL12 binding to CXCR4, for mobilisation of HSCs/HPCs into peripheral blood. (touchoncology.com)
  • It also focuses on ways to enhance the homing and engrafting capability of HSCs/HPCs that is limited by inhibition of a cell surface molecule, CD26/dipeptidylpeptidase IV (DPPIV). (touchoncology.com)
  • G-CSF is the gold standard for mobilisation of HSCs/HPCs for use in autologous and allogeneic HSC transplantation. (touchoncology.com)
  • It is postulated, but not yet definitively proved, that AMD3100 mobilises an earlier subset of HSCs than G-CSF, 11,19 and that cells mobilised with AMD3100, or the combination of AMD3100 plus G-CSF, are a higher-quality HSC than those mobilised by G-CSF. (touchoncology.com)
  • Hematopoietic stem cells (HSCs) generate all blood and immune cells, and play critical roles in the regeneration of the blood system after stress. (elifesciences.org)
  • The Laboratory of Regenerative Therapies for Inherited Blood Disorders, led by Dr. Andre Larochelle, is investigating novel strategies and stem cell concepts that can help advance the translational regenerative field, with a focus on inherited disorders affecting blood-forming hematopoietic stem cells (HSCs). (nih.gov)
  • The program aims to harness the regenerative potential of hematopoietic stem cells (HSCs), which are the cornerstone of the body's blood-forming system. (nih.gov)
  • Clinical trials have shown EPAG to be effective in stimulating residual HSCs, thereby improving blood counts across all cell lineages. (nih.gov)
  • These iPSCs are generated from the patient's own cells, corrected for the genetic defect, and then differentiated into HSCs. (nih.gov)
  • Therapeutic Candidate or Device Autologous CD34+ hematopoietic stem cells (HSCs) transduced with a lentiviral vector encoding the human ADA gene (or 'OTL-101') Indication Adenosine Deaminase - Severe Combined Immunodeficiency (or ADA-SCID) Therapeutic Mechanism This project will lead to a License Application for OTL-101 as a treatment for ADA-SCID. (ca.gov)
  • ABSTRACT This study examined haematopoietic stem cells of 19 high-risk cases of myelodysplastic syndrome (MDS) for apoptotic and anti-apoptotic signals and cellular proliferation and correlated these with clinical and cytogenetic subtypes, particularly trisomy 8. (who.int)
  • A) CD34+ cells are painted in the lympho-mononuclear region. (koreamed.org)
  • Fig. 4 Distribution of CD106, CD135, CD11a, CD44, CD49d, and CD184 assessed in mononuclear cells of the BMA, before and after mobilization according to the yield of CD34+ cells obtained via LGV. (koreamed.org)
  • Some patients have more than sufficient progenitors in a single leukapheresis while others mobilize poorly and require several apheresis procedures. (medscape.com)
  • Twenty-seven percent of responding metastatic breast cancer patients remain progression-free a median 29 months following one intensification course of cyclophosphamide (6,000 mg/m2), thiotepa (500 mg/m2), and carboplatin (800 mg/m2) (CTCb) with autologous bone marrow transplantation (ABMT). (nih.gov)
  • 1. Mobilization of peripheral blood progenitor cells following CHOP treatment combined with delayed granulocyte colony-stimulating factor administration in patients with non-Hodgkin's lymphoma. (nih.gov)
  • 5. Mobilization of peripheral blood stem cells by granulocyte-colony stimulating factors: comparison of a standard dose of glycosylated and mutated granulocyte-colony stimulating factor in non-Hodgkin's lymphoma patients following CHOP therapy. (nih.gov)
  • 12. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells. (nih.gov)
  • Patients who undergo HSCT experience a sequential suppression of host defenses, resulting in varying infectious risk at different phases of the transplantation process. (medscape.com)
  • We evaluated the ability of CD34+ hematopoietic stem and progenitor cells (HSPCs) from MF patients (that contain the MPN-disease initiating population) to give rise to MF in xenotransplanted NSGS mice. (confex.com)
  • 5x10 4 FACS-sorted CD34+ HSPCs from the peripheral blood of MF patients with JAK2 V617F (n=12), CALR indels (n=7) and MPL W515L (n=2) were transplanted into sublethally irradiated (200rads) NSGS mice via X-ray guided intra-tibial injection. (confex.com)
  • Hematopoietic stem cell transplantation has become a major treatment option for patients with hematopoietic malignancies and immune deficiencies. (cdc.gov)
  • Tumor Cell Mobilization in Leukemia Patients: Mozobil may mobilize leukemic cells and should not be used in leukemia patients. (nih.gov)
  • Methods Patient material Bone Vincristine sulfate marrow aspirates from patients one year after ASCT and normal controls were obtained after informed consent according to institutional guidelines. (tam-receptor.com)
  • The potential mechanism by which UCBT exerts its therapeutic effect in patients with hematological diseases is largely the result of the interaction of multiple growth factors and stem/progenitor cells with the organism. (clinicaltrials.gov)
  • The first phase of the trial has been completed, and the good news is that we found long-term marking of all lineages with cells derived from PHSCs in some patients but, unfortunately, at levels (less than 0.1-1%) that are unlikely to be clinically useful for most therapeutic applications. (nih.gov)
  • Massive lymphoproliferation, bronchiectasis, increased susceptibility to bacterial and viral infections and, at a lesser extent, auto-immune manifestations and occurrence of cancer, especially B cell lymphoma, have been described for both types of APDS patients. (frontiersin.org)
  • Treatment recommendations for patients with diffuse large B-cell lymphoma (DLBCL) begin with evaluating the extent of the disease, performance status of the patient, and histologic subtypes. (medscape.com)
  • A Simple Prognostic System in Myelofibrosis Patients Undergoing Allogeneic Stem Cell Transplant: A CIBMTR/EBMT analysis. (stembook.org)
  • In primary AML BM samples from patients and the OCI-AML3 cell line, CD44 engagement by hyaluronan induced inside-out activation of VLA-4 resulting in enhanced leukemia cell adhesion on VCAM-1. (haematologica.org)
  • Thus, tions were performed, but her blood counts remained maintaining adequate intracellular concentrations of reti- normal, and reverse transcription-polymerase chain reac- noids in the relevant target cell may permit ongoing tion (RT-PCR) for the PML ⁄ RAR transcript on peripheral blood was negative, with normal blood counts assessed 4 The prolonged complete responses in our patients indi- and 6 years after diagnosis. (diseasepdf.com)
  • Yisui Shengxue granules, which is a Chinese traditional medicine, can increase hemoglobin, red blood cells, and Ret of thalassemia patients with mild, moderate, and severe anemia and thus relieve clinical anemia symptoms. (hindawi.com)
  • YSSXG attenuated anemia symptoms in patients with thalassemia mostly by increasing the proliferation of hematopoietic stem cells and decreasing the hemolysis of RBCs. (hindawi.com)
  • Majority of the patients with thalassemia require lifelong blood transfusions [ 7 ] and iron chelation therapy [ 8 , 9 ]. (hindawi.com)
  • Only a few patients have the opportunity for allogeneic transplantation of hematopoietic stem/progenitor cells, which is a curative but potentially hazardous therapy [ 10 ]. (hindawi.com)
  • Most patients were ethnic Malay, the median age at transplantation was 49.5 years. (omjournal.org)
  • One treatment option is autologous hematopoietic stem cell transplantation, but this procedure is limited to certain eligible patients. (omjournal.org)
  • Autologous peripheral blood stem cell transplantation (APBSCT) has dramatically increased worldwide involving peripheral blood stem cells as a source of hematopoietic stem cells 1 for the treatment of hematological neoplasms particularly in patients with LPD. (omjournal.org)
  • APBSCT has become the standard of care for patients newly diagnosed with MM, which has prolonged the median survival rate to five to six years 3 and in patients with relapsed high-risk diffuse large B-cell lymphoma. (omjournal.org)
  • Bone marrow and peripheral blood transplantation utilizing blood stem cells can provide curative treatment for patients with cancers and non-cancerous diseases of the blood and immune systems. (ca.gov)
  • Prior to their participation in this study, patients will undergo the following evaluations: a physical exam, blood work, breathing tests, heart-function tests, chest and sinus x-rays, and bone-marrow sampling. (nih.gov)
  • His program has initiated a phase I/II clinical trial, with interim results showing promising outcomes, including improved blood counts in over 65% of patients. (nih.gov)
  • For patients with depleted marrow HSPC reserves who may not respond well to EPAG treatment, de novo generation of HSPCs through induced pluripotent stem cells (iPSCs) offers a promising alternative. (nih.gov)
  • Omisirge may increase access to stem cell transplants, including among patients from diverse backgrounds. (cryo-cell.com)
  • This approval provides a much-needed new treatment option for patients with blood cancers and could potentially improve their outcomes. (cryo-cell.com)
  • The article by Dr. Burt provides an excellent summary of the rationale for using high-dose therapy with autologous or allogeneic bone marrow transplantation (BMT) in patients with severe autoimmune diseases (SADS). (cancernetwork.com)
  • Althoughthere is evidence that allogeneic transplantation can lead to long-termdisease remissions in patients with aplastic anemia and coincidental autoimmunedisease, given the 20% to 30% treatment-related mortality, it is unlikelythat this approach can be justified for the majority of patients with autoimmunedisease. (cancernetwork.com)
  • Immunosuppressive treatment and prolonged bed rests, during Stem Cell Treatments, often cause profound loss of both physical functioning and psychological well-being to the patients. (globalstemcells.com)
  • Similar results have been obtained from our clinic where stem cell count in patients has greatly improved over 2 weeks in PT and OT. (globalstemcells.com)
  • The NHLBI leads or sponsors studies for patients who have heart, lung, blood, or sleep related diseases or disorders. (nih.gov)
  • The allogeneic HSCT was the most frequently performed (57.14%) and the most used source of Hematopoietic progenitor cells (HPC) was the peripheral blood (54.29%) and 5.71% of these patients developed the Graft versus Host Disease (GVHD), of which one was affected by acute GVHD and another by chronic GVHD. (bvsalud.org)
  • To identify signals that support survival or outgrowth in patients, we profile rare bone marrow-derived disseminated cancer cells (DCCs) long before manifestation of metastasis and identify IL6/PI3K-signaling as candidate pathway for DCC activation. (nature.com)
  • They are detected at very low frequencies (1-2 DCCs per 10 6 BM cells 10 , 11 ) in bone marrow (BM) of ~30% of breast cancer patients with no evidence of manifest metastasis. (nature.com)
  • The 4-year survival of the 65 patients randomized to autologous peripheral blood stem cell transplantation or a second consolidation course of high-dose cytarabine was 37% and 27%, respectively. (haematologica.org)
  • For the minority of patients younger than 60 years with advanced stages of MDS, allogeneic stem cell transplantation (SCT) is usually considered the treatment of choice. (haematologica.org)
  • Hematopoietic stem cell transplantation (HSCT) with high-dose chemo-radiotherapy is frequently used in the treatment of patients with hematologic malignancies. (bmrat.org)
  • EPC-colony-forming units were measured in the peripheral blood of 107 consecutive patients with CHF with New York Heart Association (NYHA) functional class II-IV. (bmj.com)
  • If marking was successful, it would also begin to answer important questions about transplantation biology, including the relative kinetics and durability of reconstitution after transplantation with cells from the bone marrow compared with peripheral blood. (nih.gov)
  • In particular, the present invention relates to the therapeutic use of fetal or neonatal stem cells for hematopoietic (or immune) reconstitution. (justia.com)
  • Stromal cells are connective tissue cells that form the supportive structure in which the functional cells of the tissue reside. (wikipedia.org)
  • In further consequence, the increased adhesion on VCAM-1 allowed AML cells to strongly bind stromal cells. (haematologica.org)
  • Treatment of a full-thickness articular cartilage defect in the femoral condyle of an athlete with autologous bone-marrow stromal cells. (anova-irm.com)
  • Altogether, our analyses reveal that the differential behavior after gene therapy of hematopoietic stem/progenitor cells derived from either bone marrow or mobilized peripheral blood is mainly due to the distinct cell composition rather than functional differences of the infused cell products, providing new frames of references for clinical interpretation of hematopoietic stem/progenitor cell transplantation outcome. (bvsalud.org)
  • We found that vector transduction of purified CD34+ progenitor cell populations over the course of 72 to 96 hours in the presence of IL-3, IL-6, and stem cell factor (SCF) produced high (30-90%) transduction efficiencies of either bone marrow or peripheral blood progenitor cells, assayed either by standard semi-solid media colony assays or by long-term culture assays designed to study more primitive cells. (nih.gov)
  • 8. [Expansion of peripheral blood progenitors by recombinant human granulocyte colony-stimulating factor]. (nih.gov)
  • Endothelial progenitor cells (EPCs) 7 reside in the bone marrow and are found to some extent in the peripheral blood. (bmj.com)
  • The benefit-risk assessment for an individual patient depends on the patient characteristics, including disease, stage, risk factors, and specific manifestations of the disease, on characteristics of the graft, and on other available treatments or types of hematopoietic progenitor cells. (nih.gov)
  • However, T-cell depletion is associated with higher rates of graft rejection and increased vulnerability to viral and fungal infections while the T-cell population is diminished. (medscape.com)
  • However, some studies have also shown increased risk of acute and chronic graft-versus-host disease (GVHD), as compared to bone marrow. (nih.gov)
  • Further analysis indicated that peripheral-blood stem cells may reduce the risk of graft failure, whereas bone marrow may reduce the risk of chronic GVHD. (nih.gov)
  • Figure 2: The peripheral part of the graft shows the new formed bone on the same material. (ispub.com)
  • Because hematopoietic stem cell transplantation carries a significant risk of causing graft versus host disease (GVHD), the GIS transplant program includes clinical protocols and bench research to develop methods and treatments to prevent or treat acute and chronic GVHD. (nih.gov)
  • p = 0.01], but there were no significant differences in acute graft versus host disease (aGVHD) grades, infection and blood stream infection between two groups. (bmrat.org)
  • Moreover post-transplantation CD34+ bone marrow cells demonstrated Vincristine sulfate an increased sensitivity to buthionine sulfoximine a trigger for endogenous production of reactive oxygen species. (tam-receptor.com)
  • Gene expression analysis on CD34+ cells revealed a set of 195 genes including HMOX1 EGR1 FOS and SIRPA that are persistently down-regulated in mobilized peripheral blood cells and post-transplantation bone marrow compared to normal bone marrow. (tam-receptor.com)
  • In vivo, HMGN1 overexpression is linked to decreased quiescence and increased HSC activity in bone marrow transplantation. (nature.com)
  • Mobilized peripheral blood is increasingly used instead of bone marrow as a source of autologous hematopoietic stem/progenitor cells for ex vivo gene therapy. (bvsalud.org)
  • The third strategy uses targeted delivery of therapeutic genes (using viral and non-viral vectors) that either transduce host cells in vivo or stably transduce cells in vitro for subsequent implantation in vivo. (ispub.com)
  • Ethical considerations constrain the in vivo study of human hemopoietic stem cells (HSC). (aai.org)
  • Cells derived from both the marrow and peripheral blood grafts contributed to the short- and long-term marking. (nih.gov)
  • In addition, somatic gain of chromosome 21 is associated with aggressive leukemias, such as iAMP21 B cell acute lymphoblastic leukemia that has multiple extra copies of 21q22 and a very poor prognosis 13 . (nature.com)
  • They have certain immunomodulatory, immunosuppressive, and antimicrobial properties that enable them to have several therapeutic and clinical applications including: treatment of autoimmune disorders, role in hematopoietic stem cell transplantation and regenerative medicine, as well as treatment of various infections and their associated complications such as septic shock and acute respiratory distress syndrome. (intechopen.com)
  • Chronic leukemias have more mature cells than do acute leukemias. (msdmanuals.com)
  • Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation. (stembook.org)
  • Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia. (stembook.org)
  • Eligible subjects were less than 66 years of age and were planning to undergo transplantation for acute leukemia, myelodysplasia, chronic myeloid or myelomonocytic leukemia, or myelofibrosis. (nih.gov)
  • Acute exercise increases the presence of endothelial progenitor cells (EPC), thus reducing the risk of cardiovascular diseases. (globalstemcells.com)
  • 7 Conditions that induce tissue ischaemia or endothelial damage-that is, vascular trauma, 8 acute myocardial infarction 9 and unstable angina 10 -are associated with a release of angiogenic factors, including vascular endothelial growth factor (VEGF) and erythropoietin, which promote mobilisation of EPC from the bone marrow to the peripheral circulation. (bmj.com)
  • A study by Ashara and colleagues in 1979, led to the discovery of cell populations with angiogenic capacity (CACs). (globalstemcells.com)
  • Stromal cell-derived factor 1-alpha (SDF) is a potent bone marrow chemokine capable of recruiting circulating progenitor populations to injured tissue. (stanford.edu)
  • Articular cartilage regeneration with autologous marrow aspirate and hyaluronic acid: an experimental study in a goat model. (anova-irm.com)
  • While SC transplants are the standard of care for hematopoietic cancers and are gaining acceptance in the treatment of burns and corneal disorders, pioneering SC therapies directed at the regeneration of other tissues and organs (that is, the promise of regenerative medicine) are few in number, use adult rather than embryonic stem cells, and are in the early stages of clinical investigation. (biomedcentral.com)
  • Hematopoietic stem cell transplantation (HSCT) results in the alteration of several components of the immune system. (medscape.com)
  • The Hematopoietic stem cell transplantation (HSCT) is used in children as a definitive treatment for various oncological, immune deficiencies, hemoglobinopathy, and malignancies diseases that involve the hematological system, congenital metabolism disorders, among others. (bvsalud.org)
  • This is a quantitative, retrospective, observational, descriptive and analytical quantitative approach approaching the medical records of children and adolescents submitted to HSCT in a referral hospital service for this type of transplantation in the state of Rio Grande do Sul North (RN). (bvsalud.org)
  • The profile of the clinical variables presented by the children and adolescents of this study shows that the most prevalent diagnosis was ALL, the most frequent toxicities were gastrointestinal, cardiac, respiratory and hematological, the most common HSCT was allogeneic peripheral blood and the greatest cause of mortality was sepsis. (bvsalud.org)
  • Hematopoietic stem cell transplantation not responded to other therapeutic modalities, with (HSCT) is used in children as a definitive treatment an increase in survival after transplantation, for different oncological, immune deficiencies, contributing to its use (YEILIPEK, 2014). (bvsalud.org)
  • Oral mucositis (OM) is one of the most common side effects after hematopoietic stem cell transplantation (HSCT) and palifermin is used for prophylactic use to prevent OM. (bmrat.org)
  • Basic and Clinical Research The overall concept of a SCOR program focuses on scientific issues related to diseases relevant to the mission of the National Heart, Lung, and Blood, Institute (NHLBI). (nih.gov)
  • Humanized mice (hu mice) are based on the transplantation of hematopoietic stem and progenitor cells into immunodeficient mice and have become important pre-clinical models for biomedical research. (nih.gov)
  • She is currently director of the Hematology Fellowship Training Program and active in clinical branch activities in bone marrow transplantation, as well as her laboratory activities. (nih.gov)
  • The current research in my laboratory and clinical research program focuses on improving our understanding of functional characteristics of pluripotent hematopoietic stem cells (PHSCs) and using that knowledge to improve the transfer of exogenous genes into these cells in order to treat a wide variety of congenital and acquired human diseases. (nih.gov)
  • The Clinical Hematology branch has one of the few nonhuman primate hematopoietic transplantation facilities in the world, and in 1991, we began to use this model to work toward human trials of retroviral gene transfer directed at PHSCs. (nih.gov)
  • This article reviews recent studies that demonstrate the modulation of the SDF-1/CXCL12-CXCR4 axis for clinical advantage for HSC/HPC transplantation. (touchoncology.com)
  • GIS also has a basic and pre-clinical program of study of induced pluripotent stem cells (iPSC). (nih.gov)
  • 1. Sandhya R. Panch, James Szymanski, Bipin N. Savani, David F. Stroncek, Sources of Hematopoietic Stem and Progenitor Cells and Methods to Optimize Yields for Clinical Cell Therapy, Biology of Blood and Marrow Transplantation, Volume 23, Issue 8, 2017, Pages 1241-1249. (cryo-cell.com)
  • Stem cell (SC) therapies hold remarkable promise for many diseases, but there is a significant gulf between public expectations and the reality of progress toward clinical application. (biomedcentral.com)
  • Cancer cells frequently acquire abnormalities in the same chromatin regulatory pathways, which promote malignancy and may impart targetable therapeutic dependencies 2 . (nature.com)
  • The goals of the study were to assess the feasibility of using these techniques in humans before attempting trials with potentially therapeutic genes, and to compare bone marrow and 'mobilized' peripheral blood cells as sources for gene transfer targets. (nih.gov)
  • Autologous peripheral blood stem cells transplantation (APBSCT) is a therapeutic option which can be used in various hematological, neoplastic disorders including lymphoproliferative disease (LPD). (omjournal.org)
  • The present invention relates to hematopoietic stem and progenitor cells of neonatal or fetal blood that are cryopreserved, and the therapeutic uses of such stem and progenitor cells upon thawing. (justia.com)
  • Therapeutic Candidate or Device The therapeutic product candidate is autologous CD34+ hematopoietic stem/progenitor cells (HSPC) transduced with the G1XCGD lentiviral vector. (ca.gov)
  • Therapeutic Candidate or Device Autologous blood stem cells edited to restore iduronidase expression Indication Severe Mucopolysaccharidosis Type 1 (MPS1/ Hurler's syndrome) Therapeutic Mechanism Autologous blood stem cells undergo genome editing to restore the production of the missing enzyme. (ca.gov)
  • 2 The authors proposed that "targeting angiogenesis in the RV myocardium appears to be a promising approach to improve its function…[and the] use of stem cells as therapeutic agents could, hence, represent a new treatment option for PAH . (pulmonologyadvisor.com)
  • Monitor blood cell counts and platelet counts during Mozobil use. (nih.gov)
  • Proliferative responses of splenic T cells to stimulation were preserved over time. (nih.gov)
  • We also quantified the frequency of long-term engrafting cells, and the average proliferative capacity of individual engrafting cells by a competitive repopulation assay with binomial variance-covariance modeling. (johnshopkins.edu)
  • Our results suggest that although trisomy 8 cells are in a pro-apoptotic state, they are checked by the enhanced expression of anti-apoptotic signals which provide them with their proliferative advantage. (who.int)
  • De novo human T cell development in NOD- scid IL2R γ null mice was validated by 1) high levels of TCR excision circles, 2) complex TCRβ repertoire diversity, and 3) proliferative responses to PHA and streptococcal superantigen, streptococcal pyrogenic exotoxin. (aai.org)
  • We identified interleukin-6 (IL-6) trans-signaling as a pathway that (i) activates normal and premalignant cells, (ii) induces a proliferative stem/progenitor-like phenotype in mammary epithelial cells, and (iii) whose activation in DCCs depends on regulatory niche cells in BM. (nature.com)
  • We developed a lentivirus (LV)-mediated gene transfer strategy using transplanted autologous hematopoietic stem/progenitor cells (HSPCs) as a source of IL-1 receptor antagonist (IL-1RA) for systemic delivery to tissues and organs. (bvsalud.org)
  • Based on these studies, we developed an MSC-based co-culture system to optimize the transplantation outcome of clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 gene-edited (GE) human HSPCs. (bvsalud.org)
  • We show that bone marrow (BM)-MSCs produce several hematopoietic supportive and anti-inflammatory factors capable of alleviating the proliferation arrest and mitigating the apoptotic and inflammatory programs activated in GE-HSPCs, improving their expansion and clonogenic potential in vitro. (bvsalud.org)